| Keywords: |
cancer survival; treatment outcome; disease-free survival; prednisone; mortality; doxorubicin; cancer combination chemotherapy; note; adjuvant therapy; cancer radiotherapy; disease free survival; chemotherapy, adjuvant; radiotherapy, adjuvant; rituximab; cancer staging; positron emission tomography; antineoplastic agent; neoplasm staging; evidence based medicine; evidence-based medicine; cell proliferation; multiple cycle treatment; antineoplastic combined chemotherapy protocols; editorial; cyclophosphamide; vincristine; pathology; time; time factors; monoclonal antibody; antibodies, monoclonal; adjuvant chemotherapy; large cell lymphoma; lymphoma, large b-cell, diffuse; chop protocol
|
